Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/162044
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCastelo-Branco Flores, Camil-
dc.contributor.authorCancelo Hidalgo, M. J.-
dc.contributor.authorPalacios Ruiz, Lucas Santiago-
dc.contributor.authorCiria Recasens, M.-
dc.contributor.authorFernández Pareja, A.-
dc.contributor.authorCarbonell Abella, Cristina-
dc.contributor.authorManasanch, J.-
dc.contributor.authorHaya Palazuelos, J.-
dc.date.accessioned2020-05-22T12:36:23Z-
dc.date.available2020-05-22T12:36:23Z-
dc.date.issued2019-11-21-
dc.identifier.issn1369-7137-
dc.identifier.urihttp://hdl.handle.net/2445/162044-
dc.description.abstractObjective: This study aimed to compare the efficacy and safety of ossein-hydroxyapatite complex (OHC) versus calcium carbonate (CC) for preventing bone loss during perimenopause in current clinical practice.Methods: The prospective, comparative, non-randomized, open-label study included 851 perimenopausal women with basal bone mineral density (BMD) T-score ≥-2 standard deviations (SDs). Participants received either OHC (712 mg calcium/day) or CC (1000 mg calcium/day) over 3 years. BMD was evaluated by dual-energy X-ray absorptiometry at the lumbar spine (L2-L4) at baseline and after 18 and 36 months of follow-up. Adverse drug reactions (ADRs) were also recorded.Results: In women receiving OHC, BMD at the L2-L4 site remained stable over the 3-year follow-up period (mean [SD] change 0.00 [0.11] g/cm2). BMD in the CC arm decreased -3.1% (mean [SD] - 0.03 [0.11] g/cm2). Between-group differences were statistically significant (p < 0.001) and favored OHC. ADRs were more frequent in the CC group (7.7% vs. 2.7% in the OHC group; p = 0.001), affecting primarily the gastrointestinal system.Conclusion: OHC showed greater efficacy and tolerability than CC for bone loss prevention in perimenopausal women in real-world practice. As the daily dose of calcium was higher in the CC group, the differences might be linked to the ossein compound in OHC.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherTaylor and Francis-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1080/13697137.2019.1685488-
dc.relation.ispartofClimacteric, 2020, vol. 23, num. 3, p. 252-258-
dc.relation.urihttps://doi.org/10.1080/13697137.2019.1685488-
dc.rights(c) The Author(s), 2020-
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/-
dc.sourceArticles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)-
dc.subject.classificationMenopausa-
dc.subject.classificationDensitometria òssia-
dc.subject.classificationOsteoporosi-
dc.subject.otherMenopause-
dc.subject.otherBone densitometry-
dc.subject.otherOsteoporosis-
dc.titleEfficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss-
dc.typeinfo:eu-repo/semantics/article-
dc.identifier.idgrec697733-
dc.date.updated2020-05-22T12:36:23Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid31747785-
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Files in This Item:
File Description SizeFormat 
697733.pdf1.6 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons